1-3 of 3
David Panush
Close
Sort by
Journal Articles

Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma

Tatyana Feldman, MD, Larysa Sanchez, MD, Patrick Toth, MD, David Panush, MD, Lori A Leslie, MD, Alan P Skarbnik, MD, Anthony R. Mato, MD, Kar Fai Chow, MD, Ricardo Parrondo, MD, Veronica Mariotti, MD, Sejal Kothadia, MD, Zhen Wang, MD, Miguel Gonzalez, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, MD PhD, Themba Nyirenda, PhD, Ewelina Protomastro, MS, Lori A. Leslie, MD, Andre Goy, MD
Journal: Blood
Blood (2016) 128 (22): 1813.
https://doi.org/10.1182/blood.V128.22.1813.1813
Published: 2016
Journal Articles

Post-Treatment (not interim) PET-CT Scan Status Is Highly Predictive of Outcome In Mantle Cell Lymphoma Treated with R-Hypercvad or ASCT

Anthony R Mato, MD, Tania Zielonka, Tatyana Feldman, MD, Jakub Svoboda, MD, Harry Agress, MD, David Panush, MD, Mitchell Miller, MD, Patrick Toth, MD, Elise A Chong, BA, Emeline R Chong, Drew Torigian, MD, Paul M Lizott, Jr., RT, Stephen J. Schuster, MD, Scott D Rowley, MD, Michele L Donato, MD, Stuart L Goldberg, MD, Andrew L Pecora, MD, Andre Goy, MD
Journal: Blood
Blood (2010) 116 (21): 3131.
https://doi.org/10.1182/blood.V116.21.3131.3131
Published: 2010
Journal Articles

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Andre Goy, MD, Peggy Ford, Tatyana Feldman, MD, Andrew Pecora, Stuart Goldberg, MD, Michele Donato, David Siegel, David Panush, Mark S. Berger, MD
Journal: Blood
Blood (2007) 110 (11): 2569.
https://doi.org/10.1182/blood.V110.11.2569.2569
Published: 2007